Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q5HYA8
UPID:
MKS3_HUMAN
Alternative names:
Meckel syndrome type 3 protein; Transmembrane protein 67
Alternative UPACC:
Q5HYA8; B3KRU5; B3KT47; G5E9H2; Q3ZCX3; Q7Z5T8; Q8IZ06
Background:
Meckelin, also known as Transmembrane protein 67, plays a crucial role in ciliary structure and function, essential for cellular signaling and development. It is involved in centrosome migration, cilia length regulation, and stereociliary bundle orientation, highlighting its multifaceted role in cell morphology and signaling pathways.
Therapeutic significance:
Linked to a spectrum of genetic disorders including Meckel syndrome 3, Joubert syndrome 6, and Bardet-Biedl syndrome 14, Meckelin's dysfunction underscores its therapeutic significance. Understanding its role could pave the way for innovative treatments targeting these ciliopathies, offering hope for affected individuals.